MYRIAD GENETICS INC
MYRIAD GENETICS INC (MYGN): 20 pipeline candidates · ~35 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
34.8 months
D/E 1.00 · 0% dilution
Lead: Approved
20 candidates
N/A
5 buys · 0 sells (180d)
A transparent, data-derived signal for MYRIAD GENETICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$413.7M
Cash
$126.0M
Quarterly Burn
$15.7M
Runway
34.8 mo
Revenue
$200.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (20 candidates)
| Drug | Phase |
|---|---|
| BRACAnalysis CDx | Approved |
| EndoPredict | — |
| FirstGene | — |
| Foresight | — |
| Foresight Carrier Screen | — |
| Foresight Universal Plus | — |
| GeneSight | — |
| global liquid biopsy companion diagnostic | Preclinical |
| MyChoice CDx | Approved |
| myriad ultrasound systems ltd. soundscan | Approved |
Showing 10 of 20 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
202
Total value held
$513.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 125,000,000 | $122.9M |
| blackrock, inc. | 8,889,644 | $40.0M |
| vanguard capital management llc | 7,849,050 | $35.3M |
| millennium management llc | 6,668,817 | $30.0M |
| glenview capital management, llc | 5,411,978 | $24.4M |
| d. e. shaw & co., inc. | 4,499,724 | $20.2M |
| state street corp | 4,424,027 | $19.9M |
| morgan stanley | 3,168,742 | $14.3M |
| vanguard portfolio management llc | 2,582,231 | $11.6M |
| goldman sachs group inc | 2,366,092 | $10.6M |
Showing top 10 of 202 institutional holders of MYRIAD GENETICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MYRIAD GENETICS INC's pipeline?
MYRIAD GENETICS INC (MYGN) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MYRIAD GENETICS INC's lead drug candidate?
MYRIAD GENETICS INC's most advanced tracked candidate is BRACAnalysis CDx (Approved) for Help determine beneficial therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants.
What is MYRIAD GENETICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MYRIAD GENETICS INC has approximately 34.8 months of cash runway.
What is MYRIAD GENETICS INC's market capitalization?
MYRIAD GENETICS INC's market capitalization is approximately $413.7M.
Who is the CEO of MYRIAD GENETICS INC?
Mr. Samraat S. Raha is the chief executive officer of MYRIAD GENETICS INC (MYGN).
Get the full picture on MYRIAD GENETICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.